Do The Dark Clouds Over Gilead’s Trodelvy Have A Silver Lining?

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

Despite a primary endpoint miss in previously treated NSCLC in EVOKE-01, analysts say the drug still has points of differentiation from the competition. 

Gilead announced results from the EVOKE-01 study of Trodelvy • Source: Shutterstock

A key late-stage clinical trial of Gilead Sciences, Inc.’s Trodelvy (sacituzumab govitecan-hziy) failed, causing the company’s stock to drop and raising questions among analysts about its position relative to its competitor, AstraZeneca PLC/Daiichi Sankyo Co., Ltd.’s datopotamab deruxtecan (dato-DXd). But the results were not seen as entirely negative, given that EVOKE-01 was in a difficult population where dato-DXd has also seen lackluster results.

Gilead reported 22 January that the Phase III EVOKE-01 trial comparing Trodelvy, an antibody-drug conjugate (ADC) targeting TROP2, against docetaxel...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D